CMS: Drug Inflation Rebates Based On Price Hikes In Commercial, Medicare Markets

By John Wilkerson / October 6, 2022 at 5:56 PM
CMS officials said Thursday (Oct. 6) that Medicare drug inflation rebates are calculated on price hikes in both the commercial and Medicare markets, confusing lobbyists who thought that measure was stripped during the budget resolution process. The Council for Informed Drug Spending Analysis estimates the commercial market spillover from Medicare rebates will reduce employer insurance costs by $31 billion from 2023 through 2031, including a $24 billion reduction in premiums paid by employers, and reduce employee out-of-pocket premiums and cost-sharing...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.